Sociodemographic and clinical characteristics of CML study population by compliance with the survey booklet (respondents vs nonrespondents)
| Variable . | Compliance with the survey booklet . | ||
|---|---|---|---|
| Nonrespondents (n = 26) . | Respondents (n = 422) . | Total (N = 448) . | |
| Sex, n (%) | |||
| Female | 8 (30.8) | 172 (40.8) | 180 (40.2) |
| Male | 18 (69.2) | 250 (59.2) | 268 (59.8) |
| Age at study entry, y | |||
| 18-39 | 2 (7.7) | 61 (14.4) | 63 (14.1) |
| 40-59 | 13 (50.0) | 187 (44.3) | 200 (44.6) |
| 60-69 | 7 (26.9) | 91 (21.6) | 98 (21.9) |
| ≥ 70 | 4 (15.4) | 83 (19.7) | 87 (19.4) |
| Median | 54 | 57 | 57 |
| Range | 22.0-85.8 | 19.4-86.8 | 19.4-86.8 |
| Education, n (%)* | |||
| Eighth grade or less | N/A | 194 (46.0) | 194 (46.0) |
| High school | N/A | 155 (36.7) | 155 (36.7) |
| University degree or higher | N/A | 70 (16.6) | 70 (16.6) |
| Missing | N/A | 3 (0.7) | 3 (0.7) |
| Marital status, n (%)* | |||
| Divorced | N/A | 30 (7.1) | 30 (7.1) |
| Single | N/A | 42 (10.0) | 42 (10.0) |
| Married/living together | N/A | 313 (74.2) | 313 (74.2) |
| Widow | N/A | 31 (7.3) | 31 (7.3) |
| Missing | N/A | 6 (1.4) | 6 (1.4) |
| Time from diagnosis, y | |||
| Mean (SD) | 5.28 (1.56) | 5.32 (1.72) | 5.31 (1.71) |
| Median | 5.1 | 5.1 | 5.1 |
| Range | 3.0-9.0 | 3.0-12.2 | 3.0-12.2 |
| Duration of imatinib therapy, y | |||
| Mean (SD) | 5.20 (1.52) | 5.13 (1.47) | 5.13 (1.48) |
| Median | 5.1 | 5 | 5 |
| Range | 3.0-8.8 | 3.0-9.3 | 3.0-9.3 |
| ECOG performance status, n (%) | |||
| 0 | 24 (92.3) | 286 (67.8) | 310 (69.2) |
| ≥ 1 | 2 (7.7) | 136 (32.2) | 138 (30.8) |
| Sokal-risk at diagnosis, n (%) | |||
| Low (< 0.8) | 12 (46.2) | 222 (52.6) | 234 (52.2) |
| Intermediate (0.8-1.2) | 9 (34.6) | 140 (33.2) | 149 (33.3) |
| High (> 1.2) | 4 (15.4) | 46 (10.9) | 50 (11.2) |
| Missing | 1 (3.8) | 14 (3.3) | 15 (3.3) |
| Comorbidity at diagnosis, n (%) | |||
| 0 | 17 (65.4) | 269 (63.7) | 286 (63.8) |
| ≥ 1 | 9 (34.6) | 153 (36.3) | 162 (36.2) |
| Initial imatinib dose, n (%) | |||
| < 400 mg/d | 0 (0.0) | 16 (3.8) | 16 (3.6) |
| 400 mg/d | 25 (96.2) | 385 (91.2) | 410 (91.5) |
| > 400 mg/d | 1 (3.8) | 21 (5.0) | 22 (4.9) |
| Current imatinib dose, n (%) | |||
| < 400 mg/d | 1 (3.8) | 61 (14.5) | 62 (13.8) |
| 400 mg/d | 22 (84.7) | 327 (77.4) | 349 (77.9) |
| > 400 mg/d | 3 (11.5) | 34 (8.1) | 37 (8.3) |
| Dose change during treatment, n (%) | |||
| No | 16 (61.5) | 257 (60.9) | 273 (60.9) |
| Yes (at least once) | 10 (38.5) | 165 (39.1) | 175 (39.1) |
| Time to first CCyR, y | |||
| Mean (SD) | 0.90 (0.99) | 0.65 (0.62) | 0.66 (0.65) |
| Median | 0.6 | 0.5 | 0.5 |
| Range | 0.0-5.2 | 0.1-6.3 | 0.0-6.3 |
| Variable . | Compliance with the survey booklet . | ||
|---|---|---|---|
| Nonrespondents (n = 26) . | Respondents (n = 422) . | Total (N = 448) . | |
| Sex, n (%) | |||
| Female | 8 (30.8) | 172 (40.8) | 180 (40.2) |
| Male | 18 (69.2) | 250 (59.2) | 268 (59.8) |
| Age at study entry, y | |||
| 18-39 | 2 (7.7) | 61 (14.4) | 63 (14.1) |
| 40-59 | 13 (50.0) | 187 (44.3) | 200 (44.6) |
| 60-69 | 7 (26.9) | 91 (21.6) | 98 (21.9) |
| ≥ 70 | 4 (15.4) | 83 (19.7) | 87 (19.4) |
| Median | 54 | 57 | 57 |
| Range | 22.0-85.8 | 19.4-86.8 | 19.4-86.8 |
| Education, n (%)* | |||
| Eighth grade or less | N/A | 194 (46.0) | 194 (46.0) |
| High school | N/A | 155 (36.7) | 155 (36.7) |
| University degree or higher | N/A | 70 (16.6) | 70 (16.6) |
| Missing | N/A | 3 (0.7) | 3 (0.7) |
| Marital status, n (%)* | |||
| Divorced | N/A | 30 (7.1) | 30 (7.1) |
| Single | N/A | 42 (10.0) | 42 (10.0) |
| Married/living together | N/A | 313 (74.2) | 313 (74.2) |
| Widow | N/A | 31 (7.3) | 31 (7.3) |
| Missing | N/A | 6 (1.4) | 6 (1.4) |
| Time from diagnosis, y | |||
| Mean (SD) | 5.28 (1.56) | 5.32 (1.72) | 5.31 (1.71) |
| Median | 5.1 | 5.1 | 5.1 |
| Range | 3.0-9.0 | 3.0-12.2 | 3.0-12.2 |
| Duration of imatinib therapy, y | |||
| Mean (SD) | 5.20 (1.52) | 5.13 (1.47) | 5.13 (1.48) |
| Median | 5.1 | 5 | 5 |
| Range | 3.0-8.8 | 3.0-9.3 | 3.0-9.3 |
| ECOG performance status, n (%) | |||
| 0 | 24 (92.3) | 286 (67.8) | 310 (69.2) |
| ≥ 1 | 2 (7.7) | 136 (32.2) | 138 (30.8) |
| Sokal-risk at diagnosis, n (%) | |||
| Low (< 0.8) | 12 (46.2) | 222 (52.6) | 234 (52.2) |
| Intermediate (0.8-1.2) | 9 (34.6) | 140 (33.2) | 149 (33.3) |
| High (> 1.2) | 4 (15.4) | 46 (10.9) | 50 (11.2) |
| Missing | 1 (3.8) | 14 (3.3) | 15 (3.3) |
| Comorbidity at diagnosis, n (%) | |||
| 0 | 17 (65.4) | 269 (63.7) | 286 (63.8) |
| ≥ 1 | 9 (34.6) | 153 (36.3) | 162 (36.2) |
| Initial imatinib dose, n (%) | |||
| < 400 mg/d | 0 (0.0) | 16 (3.8) | 16 (3.6) |
| 400 mg/d | 25 (96.2) | 385 (91.2) | 410 (91.5) |
| > 400 mg/d | 1 (3.8) | 21 (5.0) | 22 (4.9) |
| Current imatinib dose, n (%) | |||
| < 400 mg/d | 1 (3.8) | 61 (14.5) | 62 (13.8) |
| 400 mg/d | 22 (84.7) | 327 (77.4) | 349 (77.9) |
| > 400 mg/d | 3 (11.5) | 34 (8.1) | 37 (8.3) |
| Dose change during treatment, n (%) | |||
| No | 16 (61.5) | 257 (60.9) | 273 (60.9) |
| Yes (at least once) | 10 (38.5) | 165 (39.1) | 175 (39.1) |
| Time to first CCyR, y | |||
| Mean (SD) | 0.90 (0.99) | 0.65 (0.62) | 0.66 (0.65) |
| Median | 0.6 | 0.5 | 0.5 |
| Range | 0.0-5.2 | 0.1-6.3 | 0.0-6.3 |
CML indicates chronic myeloid leukemia; CCyR, complete cytogenetic response; SD, standard deviation; and N/A, not applicable.
This was judged as N/A as this data was reported in the survey booklet.